FUBO vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

FUBO

60.8
AI Score
VS
FUBO Wins

CLOV

33.4
AI Score

Investment Advisor Scores

FUBO

61score
Recommendation
HOLD

CLOV

33score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric FUBO CLOV Winner
Forward P/E 169.4915 37.7358 CLOV
PEG Ratio 0 0 Tie
Revenue Growth 38.0% 53.1% CLOV
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 60.8/100 33.4/100 FUBO
Profit Margin -1.0% 0.4% CLOV
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY FUBO

Relative Price Performance (Last 90 Days)

FUBO 1M: -10.2% · 3M: -19.1% CLOV 1M: +3.1% · 3M: +8.6%

Current Technical Phase

FUBO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.4%), weak momentum, RSI 43

RSI (14): 43.4 · Price: $7.85

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 59

RSI (14): 58.8 · Price: $4.93

Fundamentals Snapshot

Metric FUBO CLOV
Market Cap — —
Forward P/E 17.1 27.4
Trailing P/E — 483.0
Revenue (TTM) — —
Revenue Growth 0.4% 0.5%
Gross Margin 0.1% 0.2%
Operating Margin 0.0% 0.0%
EPS -1.24 0.01
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, FUBO is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.